Form 4: Cue Biopharma CEO Daniel Passeri Increases Stake with $30,000 Stock Purchase

Cue Biopharma's CEO, Daniel Passeri, recently acquired 30,000 shares of the company's common stock at an average price of $1.03 per share.

Summary

• On December 16, 2024, Daniel R. Passeri, the CEO of Cue Biopharma, Inc., purchased 30,000 shares of the company's common stock.
• The shares were acquired at a weighted average price of $1.03, with individual prices ranging from $0.97 to $1.04.
• Following this transaction, Passeri directly owns 164,578 shares of Cue Biopharma's common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive signal, but it's a relatively small transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates